Xenon Pharmaceuticals (XENE) Stock Forecast & Price Target

$44.86

+1.55 (+3.58%)

(As of 10/18/2024 08:53 PM ET)

Xenon Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 12 Analyst Ratings

Sell
0

Hold
0

Buy
12

Based on 12 Wall Street analysts who have issued ratings for Xenon Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 11 have given a buy rating, and 1 has given a strong buy rating for XENE.

Consensus Price Target

$57.45
28.08% Upside

According to the 12 analysts' twelve-month price targets for Xenon Pharmaceuticals, the average price target is $57.45. The highest price target for XENE is $65.00, while the lowest price target for XENE is $49.00. The average price target represents a forecasted upside of 28.08% from the current price of $44.86.

XENE Analyst Ratings Over Time

Type	Current Forecast 10/22/23 to 10/21/24	1 Month Ago 9/22/23 to 9/21/24	3 Months Ago 7/24/23 to 7/23/24	1 Year Ago 10/22/22 to 10/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	11 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$57.45	$58.78	$59.11	$52.44
Forecasted Upside	28.08% Upside	46.40% Upside	35.02% Upside	57.78% Upside
Consensus Rating	Buy	Buy	Buy	Buy

[Urgent] Starlink Set For The Largest IPO In History? (Ad)

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

XENE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

XENE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Xenon Pharmaceuticals Stock vs. The Competition

Type	Xenon Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	3.08	2.79	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	28.08% Upside	13,587.63% Upside	6.20% Upside
News Sentiment Rating	Neutral News See Recent XENE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/10/2024	Raymond James 4 of 5 stars	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00	+26.84%
10/1/2024	HC Wainwright 2 of 5 stars	D. Tsao Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$53.00	+34.62%
9/3/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$55.00 ➝ $55.00	+34.44%
8/30/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Minter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/12/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$62.00 ➝ $60.00	+51.13%
8/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$65.00 ➝ $65.00	+58.34%
Have you heard of Donald Trump’s Project Crypto? (Ad) Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.” Learn More Here
8/9/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$50.00 ➝ $49.00	+19.63%
5/10/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$62.00 ➝ $60.00	+48.00%
1/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$52.00 ➝ $56.00	+23.67%
12/19/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$54.00 ➝ $59.00	+39.38%
12/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$53.00 ➝ $62.00	+48.72%
12/8/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$63.00	+61.37%
12/14/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$60.00	+57.60%
12/12/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
11/28/2022	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$50.00	+43.64%
11/11/2022	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$53.00 ➝ $49.00	+40.80%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:11 AM ET.

XENE Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Xenon Pharmaceuticals is $57.45, with a high forecast of $65.00 and a low forecast of $49.00.
: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last twelve months. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XENE shares.
: According to analysts, Xenon Pharmaceuticals's stock has a predicted upside of 28.08% based on their 12-month stock forecasts.
: Over the previous 90 days, Xenon Pharmaceuticals's stock had 1 upgrade by analysts.
: Xenon Pharmaceuticals has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, Raymond James, Royal Bank of Canada, Wedbush, and William Blair in the past 90 days.
: Analysts like Xenon Pharmaceuticals more than other "medical" companies. The consensus rating for Xenon Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how XENE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Have you heard of Donald Trump’s Project Crypto? (Ad)

Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”

Learn More Here

This page (NASDAQ:XENE) was last updated on 10/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Xenon Pharmaceuticals (XENE) Stock Forecast & Price Target